Industry Symposia
Friday, October 12, 2018
| 07:00-08:30 Hall A |
Morning Industry Symposium: Practice-changing new perspectives on genomic profiling in the management of HR+, HER2- Early Breast Cancer Supported by Genomic Health |
 |
| 07:00-08:30 Hall B |
Morning Industry Symposium: CDK4/6 inhibitors in advanced breast cancer: The future is now Supported by Pfizer |
 |
| 11:30-12:30 Hall B |
Industry Symposium: Clinical controversies in HER2+ early breast cancer Supported by Roche |
 |
| 13:30-14:30 Hall B |
Industry Symposium: New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond Supported by Novartis |
 |
Saturday, October 13, 2018
| 07:00-08:30 Hall B |
Morning Industry Symposium: Old favourites, new strategies: Chemotherapy and the treatment of MBC Supported by Eisai |
 |
| 07:00-08:30 Hall C |
Morning Industry Symposium: Attractive techniques for localisation and staging: Tools for everyone Supported by Magseed |
 |
| 11:30-13:00 Hall B |
Industry Symposium: Key issues around bone health Supported by Amgen |
 |